

October 1, 1999

8465

'99 OCT -4 MD:16

Joint Council of Allergy, Asthma and **Immunology** 

50 N. Brockway St. Suite 3-3 Palatine, IL 60067 847/934-1918 FAX 847/934-1820

Dockets Management Branch (HFA-305) Food and Drug Administration 5630 Fishers Lane, Room 1061 Rockville, MD 20852

RE: Docket No. 98N-03 13

RIN 0910 - AB74

Surgeon's and Patient Examination Gloves; Reclassification

Proposed Rule

To Whom It May Concern:

The Joint Council of Allergy, Asthma and Immunology (JCAAI) appreciates the opportunity to comment on this proposed rule. JCAAI is an organization of allergists and immunologists whose sponsors are the American Academy of Allergy, Asthma and Immunology (AAAAI) and the American College of Allergy, Asthma and Immunology (ACAAI). JCAAI represents over 4,000 physicians, most of whom are board certified by the American Board of Allergy and Immunology, a conjoint board of the American Board of Internal Medicine and the American Board of Pediatrics.

Enclosed are the comments of Dr. Kevin J. Kelly, which we solicited, on this issue. These comments completely reflect the views of the Joint Council of Allergy, Asthma and Immunology. We appreciate your consideration of our comments.

Sincerely,

Daniel Ein, M.D.

President

DE/sg enclosure Sponsoring Organizations: American Academy of Allergy, Asthma and Immunology American College of Allergy, Asthma and Immunology

Board of Directors:

Daniel Ein, M.D. President David F. Graft, M.D. President-Elect Michael S. Blaiss, M.D. Treasurer Betty B. Wray, M.D Secretary Gary N. Gross, M.D. Executive Vice President J. Spencer Atwater, M.D. William E. Berger, M.D. William W. Busse, M.D. Jean A. Chapman, M.D. Ira Finegold, M.D. John W. Georgitis, M.D. Bettina C. Hilman, M.D. James P. Kemp, M.D. Robert M. Miles, M.D. Don Q. Mitchell, M.D. Robert A. Nathan, M.D. David G. Tinkelman, M.D.

Donald W. Aaronson, M.D. Robert J. Becker, M.D. Consultants

Joseph J. Lotharius Executive Director

981-0313



Jordan N. Fink, M.D. Prefossor & Chief, Allergy-Immunology Division

Kevin J. Kelly, M.D. Professor & Chief, Pediatric Allergy

Michael C. Zacharisen, M.D. Assistant Professor of Pediatrice Asnani M. Chiu, M.D. Assistent Professor of Modicine Asthma & Allergy Center Allergy-Immunology Division Departments of Medicine and Pediatrics

September 15, 1999

Dockets Management Branch (HFA-305)
Food and Drug Administration
5630 Fishers Lane
Room 1061
Rockville, MD 20852

**RE**: Docket No. 98N • 03 13

**RIN** 0910 - **AB74** 

Surgeon's and Patient Examination Gloves; Reclassification

Proposed Rule

To whom it may concern:

I am writing in **regards** to the proposed regulation to **reclassify all** surgeon and patient examination gloves to **class II** devices and set allowable limits of powder and protein in latex surgeon and examination gloves **used** for patients in the medical field. It would commend the proposed rule change as a "**next** good step" after the labeling requirement for latex containing products that went into effect September 30, 1998. However, there continues to be a number of problems that exist with the proposed ruling of which **further** work needs to continue

First, **the** level of 1200 milligrams of protein in a glove is an unacceptably high **level** of protein and is only chosen due to the **insensitivity** of the proposed lab **method** of protein **quantification**. In addition, there is no attempt in this process to identify the allergenic protein and distinguish those proteins **from** non **allergenic** protein. This requires the USC of specific immunologic assays and not the modified Lowry Test. The modified Lowry Test is insensitive and will allow unacceptably high levels of allergen to persist in latex gloves under this ruling. Since patients have reacted adversely in skin testing to levels of **protein** as low as one microgram or **smaller**, the allowance of 1200 milligram is excessive.

Second, the reduction of powder from 260 milligram (on average) to a 120 milligram is an unacceptably high level **especially** in light of the continued allowance of protein levels in the **glove** under this proposed rule. **Data from** Europe suggest that release of allergen into the air at levels of 0.6 nanograms per cubic **meter** of air is enough to invoke symptomatic disease **in** health care workers. This is clearly **exces sive** powder to bind allergen and exceed levels that produce symptoms of latex allergy.

9000 West Wisconsin Avenue P.O. Box 1997 Milwaukee, Wiscor Jin 53201 (414) 266-6840 FAX: (414) 256-6437 Therefore, the continued work on quantitative **immunologic** assays and alternatives to powder **as** a lubricant for the donning of latex gloves is **necessary** and **should be** mandatory in **the** future. **Although** supportive of **the cverall** attempt to **place** limits of powder **and** protein **content of latex** gloves, **this rule must be looked at as merely** a first step in **reducing allergic reactions in the sensitized** health **care** workers who are exposed to those materials.

Extending the proposed **leve** of protein to latex materials other than gloves should be **considered**, especially **for** those latex products **manufactured** by a dipping process. In light **of the majority of reactions reported** to the **Food** and Drug Administration being related to **allergic** reactions **from** dipped latex products, extending this rule to **those** products makes **good** sense.

Although the **mathematical** discussion **regarding** reduction of risk of allergic reactions is clear, given the liberal new allowable limits of powder and protein in the gloves, the impact of this **rule** is likely to be overestimated. Since latex **allergic** patients adversely react **below** levels produced by the new standard, it is highly **unlikely** that the number **of** allergic reactions will **be** reduced until more drastic measures are imposed. The **reduction in allergic** reactions is unlikely to occur until a **critical** reduction (**nondetection**) in **the level** of allergen (not just protein) is achieved.

If my statements are not clear or I can be of further help in clarifying the issues, please feel free to contact me at (414) 266-6840.

Sincerely,

Kevin J. Kelly, M.D.


Professor of Pediatrics & Me dicine

Director, Pediatric Allergy & Immunology

Medical College of Wisconsin

Ken Kells ms

## Attach the Airborne Express Shippers Label within the dotted lines.





United States Shipping

- Complete applicable white sections of the U.S. Airbill. Sign and date the Airbill at the Sender's Signature line. Please press hard.
- 2. Peel off protective covering from back of Airbill.
- 3. Affix Airbill to envelope within dotted lines shown.
- When using a Drop Box follow special instructions on the Drop Box.



## International Shipping Indudes Canada & Poerto Rico Mest be typed

- Complete applicable white sections of the International Express
  Airbill. Sign and date the Airbill at the Sender's Signature line.
- 2. Place Airbill in plastic sleeve.
- 3. Peel off bottom portion from back of plastic sleeve. Do not seal top portion of the plastic sleeve to the envelope.
- 4. Affix bottom portion to envelope within the dotted lines shown.

  Airborne driver must sign Airbill before sealing.

## Limitation on Contents

The maximum acceptable contents of a Letter Express is forty (40) 8-1/2 x 11 pages. If the gross weight of the contents, envelope and airbillexceeds 1/2 pound, the next higher rate will apply. Contents must be of a size and shape which fit the envelope and allow it to be securely sealed without damage. Cash or cash equivalent should not be & tipped tems of high intrinsic value should not be shipped in Letter Express packaging.

## Limitations of Liability

Liability of Airborne Express is limited on Letter Express to \$100.00 U.S.D., unless a higher value is declared for carriage on our airbill. The maximum declared value on the Letter Express is \$500.00 U.S.D. Airborne Express shall not be liable in any event for special, incidental or consequential damages, including but not limited to loss of profits or income. Services are provided as defined in the current Airborne Express Service Guide (subject to change without notice). Copies are available upon request.

To reach your local CUSTOMER SERVICE CENTER Call 1-800-AIRBORNE (1-800-247-2676) U.S. only.